National Coverage Determination (NCD)

Fecal Occult Blood Test

190.34

Expand All | Collapse All

Tracking Information

Publication Number
100-3
Manual Section Number
190.34
Manual Section Title
Fecal Occult Blood Test
Version Number
1
Effective Date of this Version
11/25/2002
Ending Effective Date of this Version
Implementation Date
01/01/2003
Implementation QR Modifier Date

Description Information

Benefit Category
Diagnostic Laboratory Tests


Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Item/Service Description

The fecal occult blood test (FOBT) detects the presence of trace amounts of blood in stool. The procedure is performed by testing one or several small samples of one, two or three different stool specimens.

This test may be performed with or without evidence of iron deficiency anemia, which may be related to gastrointestinal blood loss. The range of causes for blood loss include inflammatory causes, including acid-peptic disease, non-steroidal anti-inflammatory drug use, hiatal hernia, Crohn's disease, ulcerative colitis, gastroenteritis, strongyloides, ascariasis, tuberculosis, and enteroamebiasis. Vascular causes include angiodysplasia, hemangiomas, varices, blue rubber bleb nevus syndrome, and watermelon stomach. Tumors and neoplastic causes include lymphoma, leiomyosarcoma, lipomas, adenocarcinoma and primary and secondary metastases to the GI tract. Drugs such as nonsteroidal anti-inflammatory drugs also cause bleeding. There are extra gastrointestinal causes such as hemoptysis, epistaxis, and oropharyngeal bleeding. Artifactual causes include hematuria, and menstrual bleeding. In addition, there may be other causes such as coagulopathies, gastrostomy tubes or other appliances, factitial causes, and long distance running.

Three basic types of fecal hemoglobin assays exist, each directed at a different component of the hemoglobin molecule.

  1. Immunoassays recognize antigenic sites on the globin portion and are least affected by diet or proximal gut bleeding, but the antigen may be destroyed by fecal flora.
  2. The heme-porphyrin assay measures heme-derived porphyrin and is least influenced by enterocolic metabolism or fecal storage. This assay does not discriminate dietary from endogenous heme. The capacity to detect proximal gut bleeding reduces its specificity for colorectal cancer screening but makes it more useful for evaluating overall GI bleeding in case finding for iron deficiency anemia.
  3. The guaiac-based test is the most widely used. It requires the peroxidase activity of an intact heme moiety to be reactive. Positivity rates fall with storage. Fecal hydration such as adding a drop of water increases the test reactivity but also increases false positivity.

Of these three tests, the guaiac-based test is the most sensitive for detecting lower bowel bleeding. Because of this sensitivity, it is advisable, when it is used for screening, to defer the guaiac-based test if other studies of the colon are performed prior to the test. Similarly, this test's sensitivity may result in a false positive if the patient has recently ingested meat. Both of these cautions are appropriate when the test is used for screening, but when appropriate indications are present, the test should be done despite its limitations.

Indications and Limitations of Coverage

Indications

  1. To evaluate known or suspected alimentary tract conditions that might cause bleeding into the intestinal tract.
  2. To evaluate unexpected anemia.
  3. To evaluate abnormal signs, symptoms, or complaints that might be associated with loss of blood.
  4. To evaluate patient complaints of black or red-tinged stools.

Limitations

  1. The FOBT is reported once for the testing of up to three separate specimens (comprising either one or two tests per specimen).
  2. In patients who are taking non-steroidal anti-inflammatory drugs and have a history of gastrointestinal bleeding but no other signs, symptoms, or complaints associated with gastrointestinal blood loss, testing for occult blood may generally be appropriate no more than once every three months.

When testing is done for the purpose of screening for colorectal cancer in the absence of signs, symptoms, conditions, or complaints associated with gastrointestinal blood loss, report the HCPCS code for colorectal cancer screening; fecal-occult blood test, 1-3 simultaneous determinations should be used.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Cross Reference

Also see the NCD for Colorectal Cancer Screening Tests (§210.3 Opens in a new window) and the Medicare Claims Processing Manual Opens in a new window, Chapter 120, Clinical Laboratory Services Based on Negotiated Rulemaking.

Claims Processing Instructions

Transmittal Information

Transmittal Number
17
Revision History

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. (TN 17 Opens in a new window) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02.  Implementation date 1/01/03. (TN AB-02-110 Opens in a new window) (CR 2130)

Other

Covered Code Lists (including narrative)

January 2025 (PDF) (ICD-10 Opens in a new window)
October 2024 (PDF) (ICD-10 Opens in a new window)
July 2024 (PDF) (ICD-10 Opens in a new window)
April 2024 (PDF) (ICD-10 Opens in a new window)
January 2024 (PDF) (ICD-10 Opens in a new window)
October 2023 (PDF) (ICD-10 Opens in a new window)
July 2023 (PDF) (ICD-10 Opens in a new window)
April 2023 (PDF) (ICD-10 Opens in a new window)
January 2023 (PDF) (ICD-10 Opens in a new window)
October 2022 (PDF) (ICD-10 Opens in a new window)
July 2022 (PDF) (ICD-10 Opens in a new window)
April 2022 (PDF) (ICD-10 Opens in a new window)
January 2022 (PDF) (ICD-10 Opens in a new window)
October 2021 (PDF) (ICD-10 Opens in a new window)
July 2021 (PDF) (ICD-10 Opens in a new window)
April 2021 (PDF) (ICD-10 Opens in a new window)
January 2021 (PDF) (ICD-10 Opens in a new window)
October 2020 (PDF) (ICD-10 Opens in a new window)
July 2020 (PDF) (ICD-10 Opens in a new window)
April 2020 (PDF) (ICD-10 Opens in a new window)
January 2020 (PDF) (ICD-10 Opens in a new window)
October 2019 (PDF) (ICD-10 Opens in a new window)
July 2019 (PDF) (ICD-10 Opens in a new window)
April 2019 (PDF) (ICD-10 Opens in a new window)
January 2019 (PDF) (ICD-10 Opens in a new window)
October 2018 (PDF) (ICD-10 Opens in a new window)
July 2018 (PDF) (ICD-10 Opens in a new window)
April 2018 (PDF) (ICD-10 Opens in a new window)
January 2018 (ICD-10 Opens in a new window)
October 2017 (ICD-10 Opens in a new window)
July 2017 (ICD-10 Opens in a new window)
April 2017 (ICD-10 Opens in a new window)
January 2017 (ICD-10 Opens in a new window)
October 2016 (ICD-10 Opens in a new window)
January 2016 (ICD-10 Opens in a new window)
October 2015 (ICD-10 Opens in a new window, ICD-9 Opens in a new window)
October 2014 (ICD-10 Opens in a new window, ICD-9 Opens in a new window)

Changes to Lab NCD Edit Software

January 2025 Opens in a new window
October 2024 Opens in a new window
July 2024 Opens in a new window
January 2024 Opens in a new window
October 2023 Opens in a new window
April 2023 Opens in a new window
January 2023 Opens in a new window
October 2022 Opens in a new window
April 2022 Opens in a new window
January 2022 Opens in a new window
October 2021 Opens in a new window
July 2021 Opens in a new window
October 2020 Opens in a new window
April 2020 Opens in a new window
January 2020 Opens in a new window
October 2019 Opens in a new window
July 2019 Opens in a new window
January 2019 Opens in a new window
October 2018 Opens in a new window
April 2018 Opens in a new window
January 2018 Opens in a new window
July 2017 Opens in a new window
April 2017 Opens in a new window
January 2017 Opens in a new window
January 2016 Opens in a new window
October 2014 Opens in a new window

National Coverage Analyses (NCAs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.

Coding Analyses for Labs (CALs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with CALs, from the Coding Analyses for Labs database.

Additional Information

Other Versions
Title Version Effective Between View the document version
Fecal Occult Blood Test 1 11/25/2002 - N/A You are here
CPT Copyright Statement
CPT only copyright 2002-2011 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
Reasons for Denial
Note: This section has not been negotiated by the Negotiated RuleMaking Committee. It includes CMS’s interpretation of it’s longstanding policies and is included for informational purposes. Tests for screening purposes that are performed in the absense of signs, symptoms, complaints, or personal history of disease or injury are not covered except as explicity authorized by statue. These include exams required by insurance companies, business establishments, government agencies, or other third parties. Tests that are not reasonable and necessary for the diagnosis or treatment of an illness or injury are not covered according to the statue. Failure to provide documentation of the medical necessity of tests may result in denial of claims. The documentation may include notes documenting relevant signs, symptoms, or abnormal findings that substantiate the medical necessity for ordering the tests. In addition, failure to provide independent verification that the test was ordered by the treating physician (or qualified nonphysician practitioner) through documentation in the physician’s office may result in denial. A claim for a test for which there is a national coverage or local medical review policy will be denied as not reasonable and necessary if it is submitted without an ICD-9-CM code or narrative diagnosis listed as covered in the policy unless other medical documentation justifying the necessity is submitted with the claim. If a national or local policy identifies a frequency expectation, a claim for a test that exceeds that expectation may be denied as not reasonable and necessary, unless it is submitted with documentation justifying increased frequency. Tests that are not ordered by a treating physician or other qualified treating nonphysician practitioner acting within the scope of their license and in compliance with Medicare requirements will be denied as not reasonable and necessary. Failure of the laboratory performing the test to have the appropriate Clinical Laboratory Improvement Act of 1988 (CLIA) certificate for the testing performed will result in denial of claims.